Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX006 in Osteoarthritis of the Knee Pain
NCT02357459Phase 3Completed
- Sponsor
- Pacira BioSciences
- Start
- Jan 2015
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone acetonide in osteoarthritis (OA), sponsored by Pacira BioSciences. Primary endpoint: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores. Started Jan 2015; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02357459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357459.